Lakefront Biotherapeutics | GLPG - Selling And Administration Expenses


Lakefront Biotherapeutics reported EUR22.5M in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
argenx SE USD 598M 181M Sep/2026
AstraZeneca USD 4.07B 1.73B Sep/2026
Biogen USD 752M 42.3M Sep/2026
Genmab DKK 205M 39M Jun/2026
Gilead Sciences USD 1.52B 70M Jun/2026
GlaxoSmithKline GBP 2.16B 39M Sep/2026
GRIFOLS EUR 326M 37M Sep/2026
Hikma Pharmaceutical USD 288M 149M Dec/2025
Incyte USD 364.27M 12.54M Sep/2026
Merck EUR 1.58B 11M Sep/2026
Neurocrine Biosciences USD 366.3M 16.8M Sep/2026
Novartis USD 3.08B 163M Sep/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sanofi EUR 2.31B 325M Sep/2026
UCB EUR 1.47B 193M Dec/2025
Vertex Pharmaceuticals USD 556.3M 25.9M Sep/2026